KR102860080B1 - 융합전-안정화된 hmpv f 단백질 - Google Patents

융합전-안정화된 hmpv f 단백질

Info

Publication number
KR102860080B1
KR102860080B1 KR1020237014520A KR20237014520A KR102860080B1 KR 102860080 B1 KR102860080 B1 KR 102860080B1 KR 1020237014520 A KR1020237014520 A KR 1020237014520A KR 20237014520 A KR20237014520 A KR 20237014520A KR 102860080 B1 KR102860080 B1 KR 102860080B1
Authority
KR
South Korea
Prior art keywords
val
delete delete
ala
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237014520A
Other languages
English (en)
Korean (ko)
Other versions
KR20230084201A (ko
Inventor
제이슨 맥렐란
칭-린 셰이
스콧 러시
니안슈앙 왕
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority to KR1020257030278A priority Critical patent/KR20250140124A/ko
Priority to KR1020257030279A priority patent/KR20250139413A/ko
Publication of KR20230084201A publication Critical patent/KR20230084201A/ko
Application granted granted Critical
Publication of KR102860080B1 publication Critical patent/KR102860080B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237014520A 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질 Active KR102860080B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020257030278A KR20250140124A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질
KR1020257030279A KR20250139413A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089978P 2020-10-09 2020-10-09
US63/089,978 2020-10-09
PCT/US2021/053944 WO2022076669A1 (en) 2020-10-09 2021-10-07 Prefusion-stabilized hmpv f proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020257030279A Division KR20250139413A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질
KR1020257030278A Division KR20250140124A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질

Publications (2)

Publication Number Publication Date
KR20230084201A KR20230084201A (ko) 2023-06-12
KR102860080B1 true KR102860080B1 (ko) 2025-09-15

Family

ID=81125547

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237014520A Active KR102860080B1 (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질
KR1020257030279A Pending KR20250139413A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질
KR1020257030278A Pending KR20250140124A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257030279A Pending KR20250139413A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질
KR1020257030278A Pending KR20250140124A (ko) 2020-10-09 2021-10-07 융합전-안정화된 hmpv f 단백질

Country Status (13)

Country Link
US (4) US11919927B2 (https=)
EP (1) EP4225364A4 (https=)
JP (2) JP7660671B2 (https=)
KR (3) KR102860080B1 (https=)
CN (1) CN116615235A (https=)
AU (2) AU2021357826A1 (https=)
CA (1) CA3195015A1 (https=)
CO (1) CO2023005373A2 (https=)
IL (3) IL320367A (https=)
MX (1) MX2023004078A (https=)
NZ (1) NZ798475A (https=)
PE (1) PE20231439A1 (https=)
WO (1) WO2022076669A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021380755A1 (en) 2020-11-13 2023-06-22 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
KR20250010642A (ko) * 2022-05-12 2025-01-21 엠에스디 인터내셔널 비즈니스 게엠베하 안정화된 융합-전 hmpv 융합 단백질
EP4578878A4 (en) * 2022-09-29 2026-03-18 Beijing Benewill Tech Development Co Ltd RECOMBINANT FUSION PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS HAVING A PRE-FUSION CONFORMATION, ITS PREPARATION PROCESS AND ITS USE
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025119162A1 (zh) * 2023-12-04 2025-06-12 深圳深信生物科技有限公司 偏肺病毒(mpv)疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025144914A1 (en) * 2023-12-26 2025-07-03 Medicovestor, Inc. Dimeric antibodies and their methods of manufacture
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025260634A1 (zh) * 2024-06-19 2025-12-26 厦门万泰沧海生物技术有限公司 Rsv和hmpv融合f蛋白及其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026033492A1 (en) * 2024-08-08 2026-02-12 Vicebio Limited Chimeric fusion proteins as human metapneumovirus (hmpv) vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180008697A1 (en) 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
EP1485468A4 (en) 2002-02-21 2007-01-03 Medimmune Vaccines Inc RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
BRPI1010175A2 (pt) 2009-06-02 2016-03-29 Keller Brian Charles "composição química que inclui um conjugado de lipídio-peg e lipossoma"
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
EP3802619A1 (en) * 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2021222639A2 (en) 2020-04-29 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant human metapneumovirus f proteins and their use
MX2022015593A (es) 2020-06-09 2023-04-03 Icosavax Inc Metodo de ensamblaje de particulas similares a virus de dos componentes.
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180008697A1 (en) 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use

Also Published As

Publication number Publication date
IL301950A (en) 2023-06-01
JP2025102893A (ja) 2025-07-08
JP2023544834A (ja) 2023-10-25
KR20250140124A (ko) 2025-09-24
IL301950B2 (en) 2025-09-01
IL320367A (en) 2025-06-01
US20240140994A1 (en) 2024-05-02
US20230357327A1 (en) 2023-11-09
WO2022076669A1 (en) 2022-04-14
AU2021357826A9 (en) 2023-07-13
KR20230084201A (ko) 2023-06-12
AU2021357826A1 (en) 2023-05-11
IL301950B1 (en) 2025-05-01
MX2023004078A (es) 2023-05-24
JP7660671B2 (ja) 2025-04-11
EP4225364A1 (en) 2023-08-16
IL321500A (en) 2025-08-01
PE20231439A1 (es) 2023-09-14
US12304930B2 (en) 2025-05-20
NZ798475A (en) 2026-03-27
US12077563B2 (en) 2024-09-03
CO2023005373A2 (es) 2023-05-19
US20250257102A1 (en) 2025-08-14
CA3195015A1 (en) 2022-04-14
US11919927B2 (en) 2024-03-05
EP4225364A4 (en) 2025-02-26
US20240376158A1 (en) 2024-11-14
AU2025208554A1 (en) 2025-08-21
KR20250139413A (ko) 2025-09-23
CN116615235A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
KR102860080B1 (ko) 융합전-안정화된 hmpv f 단백질
KR20230018394A (ko) 조작된 코로나바이러스 스파이크(들) 단백질 및 이의 사용 방법
US20240317810A1 (en) Prefusion-stabilized chimeric hmpv-rsv f proteins
EP4580671A2 (en) Prefusion-stabilized cmv gb proteins
WO2022241229A1 (en) Stabilized s2 beta-coronavirus antigens
US12616747B2 (en) Stabilized beta-coronavirus antigens
US20230277653A1 (en) Stabilized beta-coronavirus antigens
US12617820B2 (en) Engineered coronavirus spike (s) protein and methods of use thereof
BR122024021506A2 (pt) Moléculas de ácido nucleico de proteína engenheirada compreendendo um ectodomínio de proteína f de metapneumovírus (mpv), e composiçao farmacêutica
BR122025014411A2 (pt) Molécula de ácido nucleico e composição farmacêutica que compreende a mesma
JP2026503061A (ja) 融合前安定化ヒトパラインフルエンザウイルス３ｆタンパク質
WO2025212898A1 (en) Pre-fusion stabilized cchfv gp38-gn-gc glycoprotein complex
WO2025171082A1 (en) Prefusion-stabilized hsv2 gb proteins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)